Fiche société
Bial - Portela C S.A.
Traitements, essais et publications liés.
Traitements7programmes
Essais3liés
Publications12liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BIA 2-093The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects. | Épilepsie | Phase 1 | À vérifier | Portugal | À vérifier |
| Levodopa (L-DOPA) + Standard careThe purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting | Parkinson | À vérifier | À vérifier | United Kingdom | À vérifier |
| OpicaponeThe purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting | Parkinson | À vérifier | À vérifier | United Kingdom | À vérifier |
| SL-APOThe purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs. | Parkinson | À vérifier | À vérifier | Germany | À vérifier |
| BIA 2-093The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects. | Épilepsie | Phase 1 | À vérifier | Portugal | À vérifier |
| OpicaponeThe purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting | Parkinson | À vérifier | À vérifier | United Kingdom | À vérifier |
| SL-APOThe purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs. | Parkinson | À vérifier | À vérifier | Germany | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SL-APO | Parkinson | À vérifier | NCT07145190 | SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment | RECRUITING |
| Opicapone | Parkinson | À vérifier | NCT03959540 | Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease | COMPLETED |
| BIA 2-093 | Épilepsie | Phase 1 | NCT02172742 | The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin | COMPLETED |
Publications
12| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| BIA 2-093 | Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. | International journal of clinical pharmacology and therapeutics | ||
| Levodopa (L-DOPA) + Standard care | Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study. | Neurology and therapy | ||
| Opicapone | Recent Developments in the Drug Treatment of Parkinson's Disease. | Drugs | ||
| Opicapone | Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. | Annals of medicine | ||
| SL-APO | Sublingual apomorphine in the treatment of Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) | ||
| SL-APO | Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. | Therapeutic advances in neurological disorders | ||
| Levodopa (L-DOPA) + Standard care | Juvenile Parkinson's disease: Symptom burden and treatment challenges. | Journal of Parkinson's disease | ||
| Levodopa (L-DOPA) + Standard care | Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. | Parkinsonism & related disorders | ||
| Opicapone | Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study. | Movement disorders : official journal of the Movement Disorder Society | ||
| Opicapone | Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease. | Movement disorders clinical practice | ||
| BIA 2-093 | Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). | Epilepsy research | ||
| BIA 2-093 | A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. | Therapeutic advances in neurological disorders |